Global Market for Epigenomic Products to be Worth $6 Billion in 2014
News Apr 26, 2010
According to a new technical market research report, EPIGENOMICS: EMERGING OPPORTUNITIES IN BIOMARKERS, DIAGNOSTICS AND THERAPEUTICS (BIO059B) from BCC Research, the global market value for epigenomic products is an estimated $930.6 million in 2009, but is expected to increase to more than $6 billion in 2014, for a 5-year compound annual growth rate (CAGR) of 45.4%.
The largest segment in the market, pharmaceuticals, is expected to increase at a 5-year CAGR of 46.4%, from $590.1 million in 2009 to nearly $4 billion in 2014.
The second-largest segment, research tools, is expected to reach $728 million in 2014. The market in 2009 is estimated to be $312.2 million. Thus, the 5-year CAGR is projected to be 18.5%.
The third-largest segment, diagnostics, is expected to increase in value from an estimated $27.1 million in 2009 to $1.2 billion in 2014, for a hefty 5-year CAGR of 114.5%.
The cell therapies segment is expected to have the highest growth rate, though it is the smallest market by far. Its projected CAGR is 150%, increasing in value from an estimated $1.2 million in 2009 to $117.3 million in 2014.
The epigenomics industry is rapidly commercializing products in a range of markets, including research tools, diagnostics, pharmaceuticals, and cell therapies. The post-genome era emphasizes epigenetic changes that are outside of DNA sequence changes as playing an important role in medicine. Scientists are cataloging and mapping epigenetic frontiers such as the human methylome and HMTome, which represent an emerging new source of biomarkers and drug targets across many diseases.
Driving the growth in therapeutics is expansion of currently approved drugs into new geographical markets in Europe and Asia, regulatory approvals of drugs in the late-stage pipeline, and expansion into new hematological and solid cancer indications.
This report will be of particular interest to the molecular diagnostics industry, pharmaceutical manufacturers, biotechnology companies, and life-science research tools companies. It also will be of interest to companies involved in drug and/or biomarker discovery programs; manufacturers of microarrays or next-generation sequencing systems, high-grade antibodies, restriction enzymes or primers; bioinformatics developers; and cancer researchers and clinicians.
Massachusetts General Hospital (MGH) researchers have found that extracellular RNA (exRNA) in urine may be a source of biomarkers for the two most common forms of muscular dystrophy, noninvasively providing information about whether therapeutic drugs are having the desired effects on a molecular level.READ MORE